Novel MiR-5088-5p Promotes Malignancy of Breast Cancer by Inhibiting DBC2

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2021 Aug 30

PMID 34457998

Citations 9

Authors

Hyun Jeong Seok

Young Eun Choi

Jae Yeon Choi

Joo Mi Yi

Eun Joo Kim

Mi Young Choi

Su-Jae Lee

In Hwa Bae

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common female cancer in the world. Despite the active research on metastatic breast cancer, the treatment of breast cancer patients is still difficult because the mechanism is not well known. Therefore, research on new targets and mechanisms for diagnosis and treatment of breast cancer patients is required. On the other hand, microRNA (miRNA) has the advantage of simultaneously regulating the expression of many target genes, so it has been proposed as an effective biomarker for the treatment of various diseases including cancer. This study analyzed the role and mechanism of DBC2 (deleted in breast cancer 2), which is known to inhibit its expression in breast cancer, and proposed microRNA (miR)-5088-5p, which regulates its expression. It was revealed that the biogenesis of miR-5088-5p was upregulated by hypomethylation of its promoter, promoted by Fyn, and was involved in malignancy in breast cancer. With the use of the cellular level, clinical samples, and published data, we verified that the expression patterns of DBC2 and miR-5088-5p were negatively related, suggesting the potential as novel biomarkers for the diagnosis of breast cancer patients.

Citing Articles

The Pivotal Function of SLC16A1 and SLC16A1-AS1 in Cancer Progress: Molecular Pathogenesis and Prognosis.

Zhou Y, Tan F, Wang Z, Zhou G, Yuan C Mini Rev Med Chem. 2024; 24(18):1685-1700.

PMID: 38616756 DOI: 10.2174/0113895575284780240327103039.

Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review.

Nie C, Shaw I, Chen C J Pharm Anal. 2024; 13(12):1429-1451.

PMID: 38223444 PMC: 10785256. DOI: 10.1016/j.jpha.2023.08.009.

The Intricate Interplay between Cancer Stem Cells and Oncogenic miRNAs in Breast Cancer Progression and Metastasis.

Tsintarakis A, Papalouka C, Kontarini C, Zoumpourlis P, Karakostis K, Adamaki M Life (Basel). 2023; 13(6).

PMID: 37374142 PMC: 10301419. DOI: 10.3390/life13061361.

Advances in the expression and function of Fyn in different human tumors.

Liu C, Li S, Tang Y Clin Transl Oncol. 2023; 25(10):2852-2860.

PMID: 37093456 DOI: 10.1007/s12094-023-03167-9.

Hsa_circ_0001925 promotes malignant progression in triple-negative breast cancer via miR-1299/YY1 axis.

Shen B, Yang Y, Zhang X Thorac Cancer. 2023; 14(8):746-757.

PMID: 36754085 PMC: 10008682. DOI: 10.1111/1759-7714.14803.

References

Wang C, Chen C, More S, Hsiao P, Hung W, Li W . The tetraindole SK228 reverses the epithelial-to-mesenchymal transition of breast cancer cells by up-regulating members of the miR-200 family. PLoS One. 2014; 9(6):e101088. PMC: 4072721. DOI: 10.1371/journal.pone.0101088. View

Dai X, Cheng H, Bai Z, Li J . Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017; 8(16):3131-3141. PMC: 5665029. DOI: 10.7150/jca.18457. View

Zubor P, Kubatka P, Dankova Z, Gondova A, Kajo K, Hatok J . miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer. Future Oncol. 2018; 14(18):1847-1867. DOI: 10.2217/fon-2018-0061. View

Garcia V, Garcia J, Pena C, Silva J, Dominguez G, Lorenzo Y . Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett. 2008; 263(2):312-20. DOI: 10.1016/j.canlet.2008.01.008. View

Shi Y, Chen J, Yang J, Li B, Chen Z, Xiao C . DBC2 gene is silenced by promoter methylation in bladder cancer. Urol Oncol. 2008; 26(5):465-9. DOI: 10.1016/j.urolonc.2007.08.009. View

Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y . Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2017; 7(1):13856. PMC: 5653849. DOI: 10.1038/s41598-017-14364-2. View

Shao M, Rossi S, Chelladurai B, Shimizu M, Ntukogu O, Ivan M . PDGF induced microRNA alterations in cancer cells. Nucleic Acids Res. 2011; 39(10):4035-47. PMC: 3105413. DOI: 10.1093/nar/gkq1305. View

Kopreski M, Benko F, Gocke C . Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci. 2001; 945:172-8. View

Freeman S, Cress W . RhoBTB2 (DBC2) comes of age as a multifunctional tumor suppressor. Cancer Biol Ther. 2010; 10(11):1123-5. DOI: 10.4161/cbt.10.11.13786. View

10.

Castaneda C, Agullo-Ortuno M, Fresno Vara J, Cortes-Funes H, Gomez H, Ciruelos E . Implication of miRNA in the diagnosis and treatment of breast cancer. Expert Rev Anticancer Ther. 2011; 11(8):1265-75. DOI: 10.1586/era.11.40. View

11.

McGuire A, Brown J, Kerin M . Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015; 34(1):145-55. PMC: 4368851. DOI: 10.1007/s10555-015-9551-7. View

12.

Wang W, Luo Y . MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B. 2015; 16(1):18-31. PMC: 4288941. DOI: 10.1631/jzus.B1400184. View

13.

Taylor M, Sossey-Alaoui K, Thompson C, Danielpour D, Schiemann W . TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest. 2012; 123(1):150-63. PMC: 3533297. DOI: 10.1172/JCI64946. View

14.

Thammaiah C, Jayaram S . Role of family microRNA in breast cancer. Noncoding RNA Res. 2018; 1(1):77-82. PMC: 6096426. DOI: 10.1016/j.ncrna.2016.10.003. View

15.

Je D, O Y, Ji Y, Cho Y, Lee D . The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion. Pancreas. 2014; 43(5):768-76. DOI: 10.1097/MPA.0000000000000103. View

16.

Ye P, Shi Y, An N, Zhou Q, Guo J, Long X . miR-145 overexpression triggers alteration of the whole transcriptome and inhibits breast cancer development. Biomed Pharmacother. 2018; 100:72-82. DOI: 10.1016/j.biopha.2018.01.167. View

17.

Chen W, Zhou S, Mao L, Zhang H, Sun D, Zhang J . Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis. Tumour Biol. 2016; 37(8):10011-9. DOI: 10.1007/s13277-016-5060-8. View

18.

Hamaguchi M, Meth J, von Klitzing C, Wei W, Esposito D, Rodgers L . DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A. 2002; 99(21):13647-52. PMC: 129730. DOI: 10.1073/pnas.212516099. View

19.

Gururajan M, Cavassani K, Sievert M, Duan P, Lichterman J, Huang J . SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Oncotarget. 2015; 6(42):44072-83. PMC: 4792542. DOI: 10.18632/oncotarget.6398. View

20.

Park S, Lee J, Ha M, Nam J, Kim V . miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 2008; 16(1):23-9. DOI: 10.1038/nsmb.1533. View